Just a month ago, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) snapped up portfolio company, San Mateo, CA-based Labrys Biologics, for $200 million up front and another $625 million in milestones. That deal came less than two years after Labrys was formed, and venBio partner and co-founder Corey Goodman told Xconomy at the time that venBio had contributed $8.5 million of Labrys’ $31 million Series A round plus an “extra kicker” for putting the deal together. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was 1.61% in last session and finished the day at $54.42. Traded volume was 4.88million shares in the last session and the average volume of the stock remained 5.36million shares. The beta of the stock remained 0.67.

Exelixis Inc (NASDAQ:EXEL) was the recipient of a significant decrease in short interest in the month of June. As of June 13th, there was short interest totalling 48,357,190 shares, a decrease of 1.5% from the May 30th total of 49,073,148 shares. Exelixis, Inc. (NASDAQ:EXEL) rose 4.65 percent to $3.60 Wednesday on volume of 4.92million shares. The intra-day range of the stock was $3.44 to $3.65. Exelixis, Inc. (NASDAQ:EXEL) has a market capitalization of $700.90million.

Earlier in June, Novavax Inc. (NASDAQ:NVAX) announced a $100 million secondary offering of common stock. The underwriters are JPMorgan (JPM) and Citibank (C) , two global investment banks that currently do not cover the stock from a research standpoint. Novavax, Inc. (NASDAQ:NVAX)’s stock on July 02, 2014 reported a increase of 3.09% to the closing price of $5.01. Its fifty two weeks range is $2.09 -$6.95. The total market capitalization recorded $1.19billion. The overall volume in the last trading session was 5.31million shares. In its share capital, NVAX has 234.31million outstanding shares.

Abbott Laboratories (NYSE:ABT) continues to lead the investment trend in emerging nations with about 50% of sales coming in from this market. The company expects this contribution to climb to 60% by 2015. On Wednesday, shares of Abbott Laboratories (NYSE:ABT) advanced 1.48% to close the day at $41.79. Company return on investment (ROI) is 8.00% and its monthly performance is recorded as 4.95%. Abbott Laboratories (NYSE:ABT) quarterly revenue growth is 8.97%.

GlobeImmune has inked collaboration agreements with Gilead Sciences Inc., for a drug to treat chronic hepatitis B virus, and with Celgene Corp. (NASDAQ:CELG), for oncology products. Those two partnerships have combined for more than $60 million in revenue for GlobeImmune as of March 31, according to a filing made Monday with the U.S. Securities and Exchange Commission. Celgene Corporation (NASDAQ:CELG) stock performance was 1.77% in last session and finished the day at $90.07. Traded volume was 5.94million shares in the last session and the average volume of the stock remained 5.95million shares. The beta of the stock remained 1.15. Celgene Corporation (NASDAQ:CELG) insider ownership is 0.20%.